Early Aortic Valve Replacement of Asymptomatic Severe Aortic Stenosis: A Meta‐Analysis of Randomized Controlled Trials
Journal of the American Heart Association · 19.08.2025 · 14 (16)
DOI: 10.1161/jaha.125.041283 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of the American Heart Association, erschienen am 19.08.2025. Verfasst von Qingchun Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, The Second Xiangya Hospital Central South University Changsha Hunan China. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Heart Valve Prosthesis Implantation, Aortic Valve, Time-to-Treatment. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Asymptomatic severe aortic stenosis may lead to the progression to both symptoms and adverse outcomes if left untreated. The appropriate timing of intervention for these patients remains controversial, and any decision requires careful assessment.
Methods
We searched PubMed, Web of Science, EMBASE, and Cochrane Library for randomized controlled trials comparing early aortic valve replacement with conservative management in asymptomatic patients with severe aortic stenosis until December 2024. The primary efficacy outcome was a composite of all‐cause mortality, hospitalization for cardiovascular causes, stroke, and myocardial infarction. We expressed outcome data as risk ratios (RRs) with 95% CIs.
Results
We included 4 randomized controlled trials involving 1427 patients. Early aortic valve replacement significantly reduced the incidence of the composite outcome when compared with conservative management (29.2% versus 53.7%; RR, 0.56 [95% CI, 0.49–0.64]; I 2 =60%). Significant reductions were also detected in all‐cause mortality (10.0% versus 13.7%; RR, 0.74 [95% CI, 0.55–0.99]; I 2 =58%), hospitalization for cardiovascular causes (14.6% versus 32.5%; RR, 0.48 [95% CI, 0.39–0.58]; I 2 =26%), and stroke (4.5% versus 7.2% RR, 0.62 [95% CI, 0.40–0.95]; I 2 =0%). No significant difference was observed in cardiac‐specific mortality (8.3% versus 16% RR, 0.68 [95% CI, 0.40–1.16]; I 2 =65%) and myocardial infarction (0.6% versus 4.6%; RR, 0.21 [95% CI, 0.04–1.19]; I 2 =0%).
Conclusions
Our meta‐analysis of randomized controlled trials showed that among patients with asymptomatic severe aortic stenosis, a strategy of early aortic valve interventions was superior to conservative treatments in reducing the primary composite outcome of all‐cause mortality, hospitalization for cardiovascular causes, stroke, and myocardial infarction. However, significant differences in the rates of cardiac‐specific mortality were not apparent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, The Second Xiangya Hospital Central South University Changsha Hunan China.
- Department of Plastic and Aesthetic(Burn)Surgery, Second Xiangya Hospital Central South University Changsha China.
- Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital Central South University Changsha China.
ORCID-Profile: Qingchun Song, Ruilin Liu, Xiaokang Tu, Haoyu Tan, Chengming Fan, Xiaoxiao Li
Zitieren
APA
Song, Q., Liu, R., Yang, K., Tu, X., Tan, H., Fan, C., & Li, X. (2025). Early Aortic Valve Replacement of Asymptomatic Severe Aortic Stenosis: A Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 14(16). https://doi.org/10.1161/jaha.125.041283
Vancouver
Song Q, Liu R, Yang K, Tu X, Tan H, Fan C, et al. Early Aortic Valve Replacement of Asymptomatic Severe Aortic Stenosis: A Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2025;14(16). doi:10.1161/jaha.125.041283
BibTeX
@article{Song2025,
author = {Song, Qingchun and Liu, Ruilin and Yang, Kai and Tu, Xiaokang and Tan, Haoyu and Fan, Chengming and Li, Xiaoxiao},
title = {Early Aortic Valve Replacement of Asymptomatic Severe Aortic Stenosis: A Meta‐Analysis of Randomized Controlled Trials},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {16},
doi = {10.1161/jaha.125.041283}
}
EUVIMED